Canopy Growth

CGC

Market cap $486M

Marijuana stock investors are still in a position where volatility and speculation control the outcome. Especially with all the laws and regulatory changes that have transformed the cannabis industry. All of which has an impact on how the public sector behaves. When an investor speculates, whether for better or worse, it can lead to others following suit, and this typically creates more momentum for the sector as a whole. As the current state of the cannabis sector has not changed much in this regard, investors are keeping a close eye on any upward shifts in trading.

In the latest trading session, Canopy Growth Corporation (CGC) closed at $1.08, marking a +2.86% move from the previous day.

Marijuana stock investors who have been trading and holding over the years know this sector holds potential. Now, potential doesn't put money in your pocket, but progressive and profitable companies that make up the industry can, which means that there is a lot of potential to see big gains in the future with all that is taking place. For the USA, there are only a few states that have yet to legalize cannabis. Just the legal states alone in 2026 have brought in a billion in revenue.

Recently, Zacks.com users have been paying close attention to Canopy Growth (CGC). This makes it worthwhile to examine what the stock has in store.

In the latest trading session, Canopy Growth Corporation (CGC) closed at $1.02, marking a +2% move from the previous day.

The Canadian cannabis sector continues evolving as global opportunities expand. Many companies are now positioning for U.S. entry. Additionally, federal reform discussions in the United States remain a major catalyst. As a result, investors are closely watching key Canadian names. However, volatility remains high, so proper risk management is essential.

SMITH FALLS, Ontario--(BUSINESS WIRE)--Canopy Growth Corporation (“Canopy Growth” or the “Company”) (TSX: WEED) (Nasdaq: CGC) today announced Deelish ("DEE-LISH"), a new cannabis brand built for the everyday consumer with an everyday price. Deelish enters the market built to deliver high THC with flower testing at 27%-33% THC and pre-rolls at 26%-32% THC. And unlike brands built around a single profile, Deelish rotates its genetic lineup regularly, giving consumers access to a curated range of.

Marijuana legalization in the U.S. isn't likely to happen anytime soon, and that's weighing on Canopy Growth's stock. The company's results have been abysmal, and there's little reason to be optimistic that they'll improve anytime soon.

SMITH FALLS, Ontario--(BUSINESS WIRE)--Canopy Growth Corporation (“Canopy Growth” or the “Company”) (TSX: WEED) (Nasdaq: CGC) today announced that its Apollo Cannabis Clinics (“Apollo”) has been named Best Medical Cannabis Clinic in the 2025 Toronto Star's Readers' Choice Awards, a public vote that reflects the trust patients place in Apollo's care. Apollo represents the Company's commitment to raising the standard of medical cannabis and making quality treatment accessible to every Canadian. “.

SMITH FALLS, Ontario & TUTTLINGEN, Germany--(BUSINESS WIRE)--Canopy Growth Corporation (“Canopy Growth” or the “Company”) (TSX: WEED) (Nasdaq: CGC) today announced the appointment of David Männer as Managing Director of Storz & Bickel, a subsidiary of Canopy Growth, effective April 1, 2026. Mr. Männer succeeds Jürgen Bickel, Storz & Bickel's Co-founder, who has decided to transition out of his role. Founded in 2001, Storz & Bickel has grown into a global leader in vaporization techn.